TY - JOUR
T1 - Umbilical Cord Blood Transplantation
T2 - Connecting Its Origin to Its Future
AU - Sanchez-Petitto, Gabriela
AU - Rezvani, Katayoun
AU - Daher, May
AU - Rafei, Hind
AU - Kebriaei, Partow
AU - Shpall, Elizabeth J.
AU - Olson, Amanda
N1 - Publisher Copyright:
© The Author(s) 2023. Published by Oxford University Press.
PY - 2023/3/3
Y1 - 2023/3/3
N2 - Transplantation of umbilical cord blood (UCB) is an attractive alternative source of hematopoietic stem cells (HSCs). The unique properties of cord blood and its distinct immune tolerance and engraftment kinetics compared to bone marrow (BM) and peripheral blood progenitor cells, permit a wider disparity in human leukocyte antigen levels between a cord blood donor and recipient after an unrelated umbilical cord blood transplant (UCBT). In addition, it is readily available and has a lowered risk of graft-versus-host disease (GvHD), with similar long-term clinical outcomes, compared to BM transplants. However, the relatively low number of cells administered by UCB units, as well as the associated delayed engraftment and immune reconstitution, pose limitations to the wide application of UCBT. Research into several aspects of UCBT has been evaluated, including the ex vivo expansion of cord blood HSCs and the process of fucosylation to enhance engraftment. Additionally, UCB has also been used in the treatment of several neurodegenerative and cardiovascular disorders with varying degrees of success. In this article, we will discuss the biology, clinical indications, and benefits of UCBT in pediatric and adult populations. We will also discuss future directions for the use of cord blood.
AB - Transplantation of umbilical cord blood (UCB) is an attractive alternative source of hematopoietic stem cells (HSCs). The unique properties of cord blood and its distinct immune tolerance and engraftment kinetics compared to bone marrow (BM) and peripheral blood progenitor cells, permit a wider disparity in human leukocyte antigen levels between a cord blood donor and recipient after an unrelated umbilical cord blood transplant (UCBT). In addition, it is readily available and has a lowered risk of graft-versus-host disease (GvHD), with similar long-term clinical outcomes, compared to BM transplants. However, the relatively low number of cells administered by UCB units, as well as the associated delayed engraftment and immune reconstitution, pose limitations to the wide application of UCBT. Research into several aspects of UCBT has been evaluated, including the ex vivo expansion of cord blood HSCs and the process of fucosylation to enhance engraftment. Additionally, UCB has also been used in the treatment of several neurodegenerative and cardiovascular disorders with varying degrees of success. In this article, we will discuss the biology, clinical indications, and benefits of UCBT in pediatric and adult populations. We will also discuss future directions for the use of cord blood.
KW - adult hematopoietic stem cells
KW - cord blood
KW - stem cell transplantation
KW - stem/progenitor cell
KW - umbilical cord blood
UR - http://www.scopus.com/inward/record.url?scp=85149998969&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85149998969&partnerID=8YFLogxK
U2 - 10.1093/stcltm/szac086
DO - 10.1093/stcltm/szac086
M3 - Article
C2 - 36779789
AN - SCOPUS:85149998969
SN - 2157-6564
VL - 12
SP - 55
EP - 71
JO - Stem Cells Translational Medicine
JF - Stem Cells Translational Medicine
IS - 2
ER -